Experts' Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach

作者全名："Zhao, Zuotao; Gao, Xing-Hua; Li, Wei; Wang, Hua; Liang, Yunsheng; Tang, Jianping; Yao, Xu; Zhao, Hua; Luger, Thomas"

作者地址："[Zhao, Zuotao] Peking Univ First Hosp, Natl Clin Res Ctr Skin & Immune Dis, Dept Dermatol & Venereol, 8 Xishiku St, Beijing, Peoples R China; [Gao, Xing-Hua] China Med Univ, Hosp 1, Dept Dermatol, 77 Puhe Rd, Shenyang, Liaoning, Peoples R China; [Li, Wei] Fudan Univ, Huashan Hosp, Dept Dermatol, 796 Jiangsu Rd, Shanghai, Peoples R China; [Wang, Hua] Chongqing Med Univ, Childrens Hosp, Dept Dermatol, 136 Zhongshan 2nd Rd, Chongqing, Peoples R China; [Liang, Yunsheng] Southern Med Univ, Dermatol Hosp, Dept Dermatol, Nanfang Ave, Guangzhou, Guangdong, Peoples R China; [Tang, Jianping] Hunan Childrens Hosp, Dept Dermatol, 86 Ziyuan Rd, Changsha, Hunan, Peoples R China; [Yao, Xu] Chinese Acad Med Sci & Peking Union Med Coll, Hosp Skin Dis, Inst Dermatol, Dept Allergy & Rheumatol, 9 Dongdan 3rd Alley, Beijing, Peoples R China; [Zhao, Hua] Chinese Peoples Liberat Army Gen Hosp, Dept Dermatol & Venereol, 4th Ring Rd, Beijing, Peoples R China; [Luger, Thomas] Univ Munster, Dept Dermatol, Von Esmarch Str 58, D-48149 Munster, Germany"

通信作者："Luger, T (通讯作者)，Univ Munster, Dept Dermatol, Von Esmarch Str 58, D-48149 Munster, Germany."

来源：DERMATOLOGY AND THERAPY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000771544700001

JCR分区：Q1

影响因子：3.4

年份：2022

卷号：12

期号：4

开始页：933

结束页：947

文献类型：Article

关键词：China; Consensus; Pimecrolimus

摘要："Introduction Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease with rising prevalence. Topical corticosteroids (TCS) are recommended as first-line therapy for patients with AD in China; however, corticophobia is a widespread concern, which can manifest as noncompliance: in a previous Chinese study, almost all parents whose children had AD were very concerned about the side effects of TCS and, as a result, nearly half did not use it in the event of recurrence. We propose a TCS-sparing treatment algorithm for the management of infants, children, adolescents, and adults with mild-to-moderate AD, to guide clinical practice in China. Methods A panel of eight experts in AD from China and one expert from Germany formed to develop a practical algorithm for the management of mild-to-moderate AD, focusing on pimecrolimus. Results Irrespective of body location, all patients with mild AD (including acute flares) and infants with moderate AD should apply the topical calcineurin inhibitor (TCI) pimecrolimus twice daily to the affected area until symptoms disappear. For children, adolescents, and adults with moderate AD, pimecrolimus should be applied twice daily to sensitive skin areas, and a TCI (either pimecrolimus or tacrolimus) should be applied twice daily to other body locations. Short-term administration of TCS, followed by TCI twice daily, is recommended for most patients with moderate AD experiencing acute flares, regardless of lesion site. Emollients should be used regularly. Conclusions The algorithm presented intends to simplify treatment of AD in China and guide clinical decision-making."

基金机构："Meda Pharma S.p.A., a Viatris company"

基金资助正文："The writing/editorial support/journal Rapid Service fee were funded by Meda Pharma S.p.A., a Viatris company. All authors were invited to a workshop funded by Viatris, in which travel and accommodation were paid."